¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Review of public data use."¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • drug utilization review
    ¾à¹°»ç¿ë°ËÅä
  • Institutional Review Board
    »ý¸íÀ±¸®À§¿øÈ¸
  • retrospective review
    ÈÄÇâÆò°¡
  • review
    °ËÅä, Æò°¡
  • review of system
    ü°èº°¹®Áø
  • data
    ÀÚ·á
  • data acquisition
    ÀÚ·á¼öÁý
  • data clipping
    ÀÚ·áÀý´Ü
  • data clipping artifact
    ÀÚ·áÀý´ÜÀΰø¹°
  • data display
    ÀÚ·áÇ¥½Ã
  • data processing
    ÀÚ·áó¸®
  • material safety data sheet
    ¹°Áú¾ÈÀüÀÚ·á¿ëÁö
  • public access defibrillator
    ÀϹݴëÁß¼¼µ¿Á¦°Å±â
  • public antigen
    °øÀ¯Ç׿ø
  • public exposure
    °ø°øÇÇÆø, °ø°ø³ëÃâ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • review
    °ËÅä, Æò°¡
  • data
    ÀÚ·á
  • baseline data
    ±âÃÊÀÚ·á
  • public health agency
    °øÁߺ¸°Ç±â°ü
  • public health center
    º¸°Ç¼Ò
  • public exposure
    °øÁßÇÇÆø, °øÁß³ëÃâ
  • public health
    °øÁߺ¸°Ç
  • public hazard
    °øÇØ
  • public hygiene
    °øÁßÀ§»ý
  • public health service
    °øÁߺ¸°Ç»ç¾÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • concurrent review
    ÀÔ¿øÁßÁ¶»ç, µ¿½ÃÆò°¡
  • drug utilization review
    ¾à¹°»ç¿ë°ËÅä
  • review
    Á¶»ç, Æò°¡
  • retrospective review
    Åð¿øÈÄÁ¶»ç, »çÈÄÆò°¡
  • utilization review
    ÀÇ·áÀ̿뵵Á¶»ç
  • data acquisition
    ÀÚ·á¼öÁý
  • data clipping artifact
    ÀÚ·áÀý´ÜÀΰø¹°
  • baseline data
    ±âÃÊÀÚ·á
  • blood gas data
    Ç÷¾×°¡½º°Ë»çÀÚ·á
  • clinical data
    ÀÓ»óÀÚ·á
  • data clipping
    ÀÚ·áÀý´Ü
  • data
    ÀÚ·á, Àç·á, µ¥ÀÌÅÍ
  • data display
    ÀÚ·áÇ¥½Ã
  • data processing
    ÀÚ·áó¸®
  • discrete data
    ÀÌ»êÀÚ·á
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • professional standard review organization(PSRO)
    ÀÇ·áÆò°¡¿ø.
  • hallucinogen use disorder
    ȯ°¢Á¦»ç¿ëÀå¾Ö(º´)(ü³ÊÆð¥ÞÅéÄî¡äô)
  • harmful use
    À¯ÇØ<ÇØ·Î¿î>»ç¿ë(êóúªÞÅéÄ)
  • phencyclidine use disorder
    Ææ½ÎÀÌŬ¸®µò »ç¿ëÀå¾Ö(º´)
  • Clinical data
    ÀÓ»óÀÚ·á
  • Data analysis
    Á¤º¸ºÐ¼®
  • MSDS => Material Safety Data Sheet
    ¹°Áú¾ÈÀüÀÚ·á¿ëÁö
  • identifying data
    ½Å»óÀÚ·á
  • PSTN (public switched telephone network)
    °øÁß ÀüÈ­¸Á, °øÁß ÀüÈ­ ±³È¯¸Á
  • antigen, public
    ÀϹÝÇ׿ø, °øÅëÇ׿øcf.private antigen
  • public antigen
    °øÅëÇ׿ø
  • public antigen
    ÀϹÝÇ׿ø, °øÅëÇ׿ø cf.private antigen
  • public exposure
    °øÁßÇÇÆø
  • public hazard =p. nuisance
    °øÇØ(Ë­Ì´).
  • public health
    °øÁߺ¸°Ç(ÇÐ)(Ë­Ì¡ËÓ˧̰).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • concurrent review
    ÀÔ¿ø Áß Á¶»ç, µ¿½ÃÆò°¡
  • drug utilization review
    ¾à¹°»ç¿ë °ËÅä.
  • life review
    Àλý¹ÝÃß(ìÑßæÚãõÖ)
  • peer review
    µ¿·á Àç°Ë(î¢Ëþ)
  • peer review organization(PRO)
    µ¿·á½É»çÀ§¿øÈ¸.
  • professional standard review organization(PSRO)
    ÀÇ·áÆò°¡¿ø.
  • retrospective review
    Åð¿øÈÄ Á¶»ç, »çÈÄÆò°¡.
  • utilization review
    ÀÇ·áÀ̿뵵 Á¶»ç.
  • clinical use
    ÀÓ»óÀû(ÀÎ) ÀÌ¿ë
  • excessive use
    °ú¿ë(ΦéÄ).
  • external use
    ¿Ü¿ë(èâéÄ).
  • hallucinogen use disorder
    ȯ°¢Á¦»ç¿ëÀå¾Ö(º´)(ü³ÊÆð¥ÞÅéÄî¡äô)
  • harmful use
    À¯ÇØ<ÇØ·Î¿î>»ç¿ë(êóúªÞÅéÄ)
  • internal use
    ³»¿ë(Ò®éÄ).
  • opioid use disorder
    ¾ÆÆí¾çÁ¦Á¦ »ç¿ëÀå¾Ö(º´).
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á